Merck & Co., Inc. (MRK) — Equity Initiation Report
Rating: Outperform
Time Horizon: 12–18 months
Coverage Currency: USD
Table 1: Company Snapshot and Key Financial Metrics
Most Recent Quarter: Q1 2026 (Ended March 31, 2026)
| Metric | Q1 2026 | Q1 2025 | YoY Change |
|---|---|---|---|
| Revenue ($M) | 16,286 | 15,529 | +5% |
| Gross Margin (%) | 74.2 | 78.0 | -380 bps |
| Operating Income ($M) | -3,534 | 5,903 | N/M |
| Net (Loss) Income ($M) | -4,240 | 5,079 | N/M |
| EPS (GAAP, $) | -1.72 | 2.01 | N/M |
| Non-GAAP EPS ($) | -1.28 | 2.22 | N/M |
| R&D Expense ($M) | 12,592 | 3,621 | +248% |
| FCF ($M) | 3,918 | 2,500 | +57% |
| Dividend per Share ($) | 0.85 | 0.81 | +5% |
| Share Repurchases ($M) | 874 | 1,164 | -25% |
| Cash & Investments ($M) | 6,807 | 15,521* | -56% |
| Total Debt ($M) | 49,117 | 49,339* |
*End of prior fiscal year (Dec 31, 2025)
Table 2: Key Growth Drivers and Investment Thesis
| Growth Driver / Theme | Details & Commentary |
|---|---|
| Oncology Franchise (Keytruda/QLEX) | $8.0B Q1 2026 sales (+12% YoY); Keytruda remains the world’s leading immuno-oncology drug; QLEX (SC) launch underway. |
| Pipeline Diversification | >20 new launches in progress; robust late-stage pipeline in oncology, cardiometabolic, respiratory, HIV, ophthalmology. |
| Cardiometabolic/Respiratory Launches | WINREVAIR ($525M Q1 2026, +88% YoY), OHTUVAYRE ($131M Q1 2026, first full quarter post-acquisition). |
| Animal Health | $1.8B Q1 2026 sales (+13% YoY); strong livestock growth, new launches in companion animal. |
| M&A and BD Execution | Recent acquisitions: Cidara ($9.2B, influenza prevention), Verona Pharma ($10.4B, COPD), Terns ($6.7B, CML candidate). |
| Capital Allocation | $2.1B dividends, $874M buybacks Q1 2026; dividend increased to $0.85/share; $6.4B remaining repurchase authorization. |
| Cost Optimization | Ongoing restructuring ($3B program through 2027), targeting $1.7B annual cost savings by 2027. |
Table 3: Bull Case vs Bear Case
| Scenario | Key Points |
|---|---|
| Bull Case |
|
| Bear Case |
|
Table 4: Major Risks
| Risk Category | Description |
|---|---|
| Patent Expiry/LOE | Keytruda U.S. compound patent expires Dec 2028; additional patents may extend to Nov 2029 but are litigated. |
| Regulatory/Pricing | IRA price setting for Keytruda (from 2029), Lenvima (2028), Januvia/Janumet (2026–27); MFN pricing agreement. |
| Pipeline/Clinical | Failure or delay in late-stage pipeline (oncology, cardiometabolic, HIV, immunology, ophthalmology). |
| M&A Integration | Execution risk on recent large deals (Cidara, Verona, Terns); potential for overpayment or asset write-downs. |
| China Market | GARDASIL/GARDASIL 9 sales in China remain depressed; local competition and regulatory uncertainty persist. |
| Litigation | Ongoing product liability (Gardasil, Dr. Scholl’s), antitrust, and patent litigation. |
| FX/Global Macro | ~44% of sales ex-U.S.; adverse FX, global economic slowdown, or geopolitical events could impact results. |
Narrative Analysis
Business and Segment Overview
Pharmaceuticals:
Merck’s Pharmaceutical segment accounted for $14.3B of $16.3B total Q1 2026 revenue (88%). The business is anchored by Keytruda (pembrolizumab), which generated $7.9B in Q1 2026 (+10% YoY), and its subcutaneous formulation QLEX ($128M in Q1 2026, early launch phase). Keytruda is approved in over 40 indications across 19 tumor types and 2 tumor-agnostic settings, with ongoing expansion into earlier-stage cancers and new combinations.
Other major pharmaceutical contributors include:
- Welireg (belzutifan): $199M Q1 2026 (+45% YoY), expanding in renal cell carcinoma and VHL disease.
- WINREVAIR (sotatercept-csrk): $525M Q1 2026 (+88% YoY), reshaping PAH standard of care.
- OHTUVAYRE (ensifentrine): $131M Q1 2026, first full quarter post-Verona acquisition, novel COPD maintenance therapy.
- Lynparza, Lenvima, Reblozyl: Alliance revenues continue to grow, reflecting successful partnerships.
Animal Health:
Q1 2026 sales were $1.8B (+13% YoY), with livestock up 15% and companion animal up 9%. Growth is driven by demand for ruminant and poultry products, new launches (e.g., NUMELVI JAK inhibitor for dogs), and improved supply. The Bravecto line reached $379M in Q1 2026 (+16% YoY).
Vaccines:
Q1 2026 vaccine sales declined, with GARDASIL/GARDASIL 9 down 19% YoY to $1.1B, primarily due to continued weak demand in China and Japan. U.S. sales also fell due to CDC purchasing patterns, partially offset by higher net pricing. CAPVAXIVE (pneumococcal conjugate) grew 33% to $142M, with international launches underway. ENFLONSIA (RSV mAb) contributed minimally in Q1 due to seasonality.
Pipeline, R&D, and Patent Cliff Considerations
Pipeline Strength:
Merck has over 80 Phase III studies underway, with >20 new launches in progress or anticipated. Key late-stage assets include:
- Enlicitide (oral PCSK9): NDA submission in 2026, potential blockbuster for hypercholesterolemia.
- MK-1406 (CD388, from Cidara): Long-acting influenza prevention, Phase III ongoing.
- TERN-701 (from Terns): Oral allosteric BCR::ABL1 TKI for CML, Phase 1/2.
- Tulisokibart (TL1A inhibitor): Phase III in ulcerative colitis/Crohn’s, Phase II in SSc-ILD and HS.
- MK-3000 (Wnt agonist for DME): Phase 2/3, first-in-class for diabetic macular edema.
Patent Cliff:
Keytruda’s U.S. compound patent expires December 2028; two additional patents may extend protection to May/Nov 2029, but are subject to litigation. Management expects biosimilar erosion to begin in 2028–29, with a “hill not a cliff” trajectory due to pipeline launches and SC conversion (QLEX). Other major expiries: Januvia/Janumet (May/July 2026), Bridion (July 2026), Lenvima (2028/2030).
Competitive Positioning
Oncology Leadership:
Keytruda is the global leader in immuno-oncology, with broad label and deep clinical program. The QLEX SC formulation aims to defend share as biosimilars approach. Merck’s ADC pipeline (sac-TMT, I-DXd, R-DXd) and partnerships (Kelun, Daiichi Sankyo) further strengthen the oncology franchise.
Diversification:
WINREVAIR and OHTUVAYRE provide new growth vectors in cardiopulmonary and respiratory. CAPVAXIVE and ENFLONSIA expand the vaccine portfolio. Animal Health is positioned for sustained growth, with new launches and geographic expansion.
Peer Comparison:
Merck’s pipeline breadth, commercial execution, and disciplined M&A differentiate it from peers. However, Keytruda concentration (49% of 2025 sales) remains a key risk relative to more diversified competitors.
Capital Allocation and Dividends/Buybacks
- Dividends: $2.1B paid in Q1 2026; quarterly dividend raised to $0.85/share.
- Share Repurchases: $874M in Q1 2026; $6.4B remaining authorization.
- Capex: Ongoing investment in U.S. manufacturing and R&D infrastructure.
- Balance Sheet: $6.8B cash/investments at Q1 2026; $49.1B total debt; recent term loan for Terns acquisition.
M&A Strategy
Merck has executed a series of strategic acquisitions to diversify its pipeline and offset the Keytruda LOE:
- Cidara Therapeutics ($9.2B, Jan 2026): Adds MK-1406, a long-acting influenza prevention agent.
- Verona Pharma ($10.4B, Oct 2025): Adds OHTUVAYRE, a first-in-class COPD maintenance therapy.
- Terns Pharmaceuticals ($6.7B, closing May 2026): Adds TERN-701, a novel CML candidate.
- Blackstone partnership: $700M funding for sac-TMT ADC development.
Management targets deals in the $1–15B range but is open to larger transactions if science and value align. Integration risk and return discipline are emphasized.
Valuation
As of Q1 2026, Merck trades at a premium to historical averages, reflecting confidence in its pipeline and ability to manage the Keytruda LOE. Consensus FY2026 revenue is $66.8B, with consensus GAAP EPS of $2.24 (impacted by one-time charges). Excluding the $3.62/share Cidara charge, underlying non-GAAP EPS guidance is $5.04–$5.16. The dividend yield is competitive among large-cap pharma peers.
Catalysts to Watch (Next 12 Months)
| Catalyst/Event | Timing/Status | Details/Notes |
|---|---|---|
| Terns Acquisition Close | May 2026 | Adds TERN-701 (CML) to pipeline; $5.8B charge expected |
| Enlicitide (oral PCSK9) FDA CNPV Process | H2 2026 | Potential expedited approval, major new launch |
| WINREVAIR HYPERION sBLA PDUFA | Sep 21, 2026 | FDA decision on expanded PAH label |
| WELIREG + Keytruda Adjuvant RCC PDUFA | Jun 19, 2026 | FDA decision on LITESPARK-022 data |
| WELIREG + Lenvima Advanced RCC PDUFA | Oct 4, 2026 | FDA decision on LITESPARK-011 data |
| I-DXd (ifinatamab deruxtecan) SCLC PDUFA | Oct 10, 2026 | FDA decision (Daiichi Sankyo collaboration) |
| Keytruda/Keytruda QLEX + Padcev (B15) PDUFA | Aug 17, 2026 | FDA decision for cisplatin-eligible MIBC |
| Keytruda/Keytruda QLEX + Trodelvy (D19) PDUFA | H2 2026 | FDA decision for 1L TNBC |
| MK-3000 (Wnt agonist) DME Phase 3 Data | H2 2026 | First-in-class ophthalmology readout |
| TL1A (tulisokibart) UC/Crohn’s Phase 3 Data | H2 2026 | Key immunology pipeline readouts |
| ENFLONSIA (RSV) Japan Approval | 2026 | Regulatory decision pending |
| GARDASIL China Shipments | H2 2026? | Revised contract; any 2026 revenue expected immaterial |
| Additional M&A/BD Announcements | Ongoing | Management remains active in external innovation |
Sources
- Merck & Co., Inc. 10-K for FY2025 (filed Feb 24, 2026)
- Merck & Co., Inc. Q1 2026 10-Q (filed May 4, 2026)
- Merck & Co., Inc. Q1 2026 Press Release and Earnings Call (Apr 30, 2026)
- Merck & Co., Inc. Q4 2025 Press Release and Earnings Call (Feb 3, 2026)
- Merck & Co., Inc. Q3 2025, Q2 2025, Q1 2025 Press Releases and 10-Qs
- Company consensus data (as provided)
- Management commentary and pipeline disclosures from earnings calls and filings
Note: All figures are as reported in company filings and press releases. Where consensus data is referenced, it is rounded and used for context only. This report is based solely on information available in the provided source documents as of June 16, 2026.
